Xilio Therapeutics (XLO) Operating Leases (2020 - 2026)

Xilio Therapeutics has disclosed Operating Leases across 7 years of filings, most recently posting $4.9 million for Q2 2026.

• In Q2 2026, Operating Leases fell 22.61% year-over-year to $4.9 million; the TTM figure through Jun 2026 stood at $4.9 million (down 22.61% YoY), while the FY2025 annual figure was $5.6 million, down 19.31% from the prior year.
• Operating Leases came in at $4.9 million for Q2 2026 at Xilio Therapeutics, down from $5.3 million in the prior quarter.
• In the past five years, Operating Leases ranged from a high of $9.9 million in Q1 2022 to a low of $4.9 million in Q2 2026.
• Average Operating Leases over 5 years is $7.6 million, with a median of $7.7 million recorded in 2024.
• Year-over-year, Operating Leases dropped 8.6% in 2022 and fell 22.61% in 2026.
• Over 5 years, Operating Leases stood at $9.2 million in 2022, then fell by 11.39% to $8.1 million in 2023, then slipped by 14.59% to $7.0 million in 2024, then declined by 19.31% to $5.6 million in 2025, then dropped by 13.08% to $4.9 million in 2026.
• Per Business Quant data, the three most recent Operating Leases figures were $4.9 million in Q2 2026, $5.3 million in Q1 2026, and $5.6 million in Q4 2025.